962-P: Evaluating Type 1 Diabetes (T1D) Care across All Ages with the Automated Insulin Delivery Adaptive Network (AIDANET) System in Fully Closed Loop (FCL)

Introduction and Objective: The AIDANET system uses an adaptive algorithm that removes the need for meal announcement. This may help address age-specific obstacles in T1D, as older people may struggle with diabetes technology, while younger people face hormonal changes and inconsistencies in premeal dosing. Given these challenges, the glycemic outcomes of the AIDANET system in FCL were evaluated across three age groups. Methods: This study was a randomized, crossover trial evaluating the safety and feasibility of the AIDANET system. Sensor glucose data was collected from: Adolescents (14-17 y), Young Adults (18-25 y), and Adults (26-60 y). Participants used the system in FCL during a supervised hotel setting for 5 days followed by a 7-day home period. Each cohort underwent a 14-day usual care (UC) period. Results: The Adult cohort had a significant increase in TIR and TITR by 8.0% and 9.0%, respectively (Table). TAR180 also significantly decreased by 8.1%. Young Adults exhibited non-inferior results for TBR54 between UC and FCL. For Adolescents, TIR, TITR, TAR180, TAR250, and TBR54 values were non-inferior between UC and FCL. Conclusion: Adults significantly improved their glycemic outcomes with short-term use of the FCL system. Future research with long-term wear may be needed to give the system more time to adapt to the unique needs of all age groups. J.Y. Hosseinipour: None. G.P. Forlenza: Advisory Panel; Medtronic. Research Support; Medtronic, Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Tandem Diabetes Care, Inc. Advisory Panel; Tandem Diabetes Care, Inc. Research Support; Abbott. Advisory Panel; Sequel Med Tech. L. Ekhlaspour: Other Relationship; Medtronic. Advisory Panel; Abbott, Medtronic. Consultant; Jaeb Center for Health Research. Research Support; MannKind Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Sequel Med Tech. Other Relationship; Tandem Diabetes Care, Inc. Research Support; Abbott. Other Relationship; Sanofi. J.C. Wong: Research Support; Abbott, Dexcom, Inc., Tandem Diabetes Care, Inc. E. Escobar: None. E.C. Cobry: Advisory Panel; Dexcom, Inc. M. Moscoso-Vasquez: Other Relationship; Dexcom, Inc. Research Support; Tandem Diabetes Care, Inc, National Institute of Diabetes and Digestive and Kidney Diseases. S.A. Brown: Research Support; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care, Inc, Tolerion, Roche Diabetes Care. Other Relationship; MannKind Corporation.